DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT

被引：0

作者：

Kumar, S. ^{[1
]}

Berdeja, J. ^{[2
]}

Niesvizky, R. ^{[3
]}

Lonial, S. ^{[4
]}

Laubach, J. ^{[5
]}

Hamadani, M. ^{[6
]}

Stewart, A. K. ^{[7
]}

Hari, P. ^{[8
]}

Roy, V. ^{[9
]}

Vescio, R. ^{[10
]}

Kaufman, J. ^{[11
]}

Berg, D. ^{[12
]}

Liao, E. ^{[12
]}

Rajkumar, V. ^{[1
]}

Richardson, P. ^{[5
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] New York Presbyterian Hosp, Weill Cornell Med Coll, Myeloma Ctr, New York, NY USA

[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] West Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV USA

[7] Mayo Clin, Coll Med, Scottsdale, AZ USA

[8] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA

[9] Mayo Clin, Jacksonville, FL 32224 USA

[10] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA USA

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Millennium Pharmaceut Inc, Cambridge, MA USA

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S408

引用

页码：142 / +

页数：2

共 50 条

[1] Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)
Kumar, Shaji
Berdeja, Jesus
Niesvizky, Ruben
Lonial, Sagar
Laubach, Jacob
Hamadani, Mehdi
Stewart, A. Keith
Hari, Parameswaran
Roy, Vivek
Vescio, Robert
Kaufman, Jonathan
Berg, Deborah
Liao, Eileen
Rajkumar, Vincent
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S335 - S336
[2] Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Shaji K. Kumar
Jesus G. Berdeja
Ruben Niesvizky
Sagar Lonial
Jacob P. Laubach
Mehdi Hamadani
A. Keith Stewart
Parameswaran Hari
Vivek Roy
Robert Vescio
Jonathan L. Kaufman
Deborah Berg
Eileen Liao
S. Vincent Rajkumar
Paul G. Richardson
Leukemia, 2019, 33 : 1736 - 1746
[3] Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Kumar, Shaji K.
Berdeja, Jesus G.
Niesvizky, Ruben
Lonial, Sagar
Laubach, Jacob P.
Hamadani, Mehdi
Stewart, A. Keith
Hari, Parameswaran
Roy, Vivek
Vescio, Robert
Kaufman, Jonathan L.
Berg, Deborah
Liao, Eileen
Rajkumar, S. Vincent
Richardson, Paul G.
LEUKEMIA, 2019, 33 (07) : 1736 - 1746
[4] TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION
Richardson, P.
Hofmeister, C.
Rosenbaum, C.
Htut, M.
Vesole, D.
Berdeja, J.
Liedtke, M.
Chari, A.
Smith, S.
Lebovic, D.
Raje, N.
Liao, E.
Zhang, X.
Berg, D.
Baz, R.
HAEMATOLOGICA, 2017, 102 : 317 - 318
[5] Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT)
Richardson, Paul
Hofmeister, Craig
Rosenbaum, Cara
Htut, Myo
Vesole, David
Berdeja, Jesus
Liedtke, Michaela
Chari, Ajai
Smith, Stephen
Lebovic, Daniel
Raje, Noopur
Liao, Eileen
Zhang, Xiaoquan
Berg, Deborah
Baz, Rachid
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S337 - S337
[6] Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
Richardson, Paul G.
Hofmeister, Craig C.
Rosenbaum, Cara A.
Htut, Myo
Vesole, David H.
Berdeja, Jesus G.
Liedtke, Michaela
Chari, Ajai
Smith, Stephen D.
Lebovic, Daniel
Raje, Noopur
Byrne, Catriona
Liao, Eileen
Gupta, Neeraj
Di Bacco, Alessandra
Estevam, Jose
Berg, Deborah
Baz, Rachid
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 231 - 244
[7] Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma
T V Kourelis
S K Kumar
G Srivastava
M A Gertz
M Q Lacy
F K Buadi
R A Kyle
A Dispenzieri
Leukemia, 2014, 28 : 455 - 457
[8] Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma
Kourelis, T. V.
Kumar, S. K.
Srivastava, G.
Gertz, M. A.
Lacy, M. Q.
Buadi, F. K.
Kyle, R. A.
Dispenzieri, A.
LEUKEMIA, 2014, 28 (02) : 455 - 457
[9] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon, Thierry
Venner, Christopher P.
Bahlis, Nizar J.
Offner, Fritz
White, Darrell J.
Karlin, Lionel
Benboubker, Lotfi
Rigaudeau, Sophie
Rodon, Philippe
Voog, Eric
Yoon, Sung-Soo
Suzuki, Kenshi
Shibayama, Hirohiko
Zhang, Xiaoquan
Twumasi-Ankrah, Philip
Yung, Godwin
Rifkin, Robert M.
Moreau, Philippe
Lonial, Sagar
Kumar, Shaji K.
Richardson, Paul G.
Rajkumar, S. Vincent
BLOOD, 2021, 137 (26) : 3616 - 3628
[10] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
Kumar, Shaji K.
Kapoor, Prashant
Laplant, Betsy
Muchtar, Eli
Buadi, Francis K.
Gonsalves, Wilson I.
Dingli, David
Go, Ronald S.
Warsame, Rahma
Kourelis, Taxiarchis
Lust, John A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Hwa, Yi
Fonder, Amie
Hobbs, Miriam
Leung, Nelson
Rajkumar, S. Vincent
Gertz, Morie A.
Wolfe, Eric
BLOOD, 2018, 132

← 1 2 3 4 5 →